Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Passage BIO, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 52 | 51 | −1 |
| Shares | 32.8M | 40.3M | +7.54M (+23.0%) |
| Value | $33.1M | $54.4M | +$21.3M (+64.4%) |
New holders (7)
Institutions that held Passage BIO, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vestal Point Capital, LP | 4,500,000 | $6.08M | 0.50% |
| Affinity Asset Advisors, LLC | 264,266 | $356.8K | 0.06% |
| Marshall Wace, LLP | 21,990 | $29.7K | 0.00% |
| Cubist Systematic Strategies, LLC | 11,290 | $15.2K | 0.00% |
| Federated Hermes, Inc. | 783 | $1.06K | 0.00% |
| LRI Investments, LLC | 225 | $304 | 0.00% |
| Tower Research Capital LLC (TRC) | 34 | $46 | 0.00% |
Sold out (8)
Institutions that held Passage BIO, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Weiss Multi-Strategy Advisers LLC | 242,900 | $245.0K |
| Two Sigma Securities, LLC | 40,327 | $40.7K |
| Scientech Research LLC | 18,853 | $19.0K |
| Susquehanna International Group, LLP | 18,533 | $18.7K |
| Bank of New York Mellon Corp | 13,647 | $13.8K |
| Simplex Trading, LLC | 2,089 | $2.00K |
| UBS Group AG | 1,059 | $1.07K |
| Steward Partners Investment Advisory, LLC | 1,010 | $1.02K |